Shares of DepoMed (Nasdaq:DEPO) soared Monday on news the U.S. Food and Drug Administration (FDA) approved its Gralise treatment, which will be used for painful complications related to shingles.
That wasn't the only good news though, as that also triggered a $48 million payment Abbott Laboratories (NYSE:ABT) for reaching the milestone.
Shares of DepoMed exploded to $8.38, gaining $2.14, or 34.29 percent. Trading volume was over 10 times the 3-month average.
Tuesday, February 1, 2011
DepoMed (Nasdaq:DEPO) Shares Explode on Gralise Approval
Subscribe to:
Post Comments (Atom)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
No comments:
Post a Comment